Concepts (150)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Deep Brain Stimulation | 7 | 2024 | 62 | 2.550 |
Why?
|
| Tremor | 4 | 2024 | 20 | 1.360 |
Why?
|
| Parkinson Disease | 3 | 2024 | 99 | 1.250 |
Why?
|
| Essential Tremor | 2 | 2024 | 16 | 1.140 |
Why?
|
| Brain Ischemia | 4 | 2015 | 402 | 0.940 |
Why?
|
| Thalamus | 1 | 2024 | 62 | 0.900 |
Why?
|
| Intracranial Hemorrhages | 1 | 2024 | 62 | 0.870 |
Why?
|
| Milk Proteins | 2 | 2015 | 45 | 0.860 |
Why?
|
| Antigens, Surface | 2 | 2015 | 191 | 0.820 |
Why?
|
| Connectome | 1 | 2022 | 30 | 0.810 |
Why?
|
| Capacity Building | 1 | 2022 | 22 | 0.810 |
Why?
|
| Ghrelin | 2 | 2011 | 14 | 0.760 |
Why?
|
| Spinal Dysraphism | 1 | 2019 | 16 | 0.660 |
Why?
|
| Dementia | 1 | 2022 | 247 | 0.650 |
Why?
|
| Suture Techniques | 1 | 2019 | 84 | 0.630 |
Why?
|
| Adrenomedullin | 3 | 2015 | 4 | 0.620 |
Why?
|
| Agenesis of Corpus Callosum | 1 | 2017 | 6 | 0.590 |
Why?
|
| Mismatch Repair Endonuclease PMS2 | 1 | 2017 | 9 | 0.590 |
Why?
|
| DNA Mismatch Repair | 1 | 2017 | 31 | 0.570 |
Why?
|
| Ribonuclease III | 1 | 2017 | 81 | 0.570 |
Why?
|
| Complement Factor H | 3 | 2015 | 146 | 0.560 |
Why?
|
| DEAD-box RNA Helicases | 1 | 2017 | 77 | 0.550 |
Why?
|
| Substantia Nigra | 1 | 2016 | 15 | 0.550 |
Why?
|
| Alzheimer Disease | 1 | 2022 | 556 | 0.540 |
Why?
|
| Cerebellum | 1 | 2016 | 94 | 0.520 |
Why?
|
| Microscopy, Confocal | 1 | 2016 | 219 | 0.510 |
Why?
|
| Brain | 5 | 2022 | 1488 | 0.500 |
Why?
|
| Neuroimaging | 1 | 2016 | 130 | 0.490 |
Why?
|
| Neural Stem Cells | 1 | 2015 | 43 | 0.480 |
Why?
|
| Neuroprotective Agents | 2 | 2012 | 72 | 0.470 |
Why?
|
| Inflammation | 2 | 2011 | 1097 | 0.470 |
Why?
|
| Vagus Nerve | 2 | 2011 | 22 | 0.460 |
Why?
|
| Cell Movement | 1 | 2015 | 423 | 0.420 |
Why?
|
| Intralaminar Thalamic Nuclei | 2 | 2022 | 4 | 0.400 |
Why?
|
| Anterior Thalamic Nuclei | 2 | 2022 | 4 | 0.400 |
Why?
|
| Sympatholytics | 1 | 2011 | 5 | 0.390 |
Why?
|
| Apoptosis | 3 | 2011 | 1038 | 0.390 |
Why?
|
| Sympathetic Nervous System | 1 | 2011 | 33 | 0.380 |
Why?
|
| Parasympathetic Nervous System | 1 | 2011 | 5 | 0.370 |
Why?
|
| Nitric Oxide Synthase Type I | 1 | 2011 | 6 | 0.370 |
Why?
|
| Cell Proliferation | 1 | 2015 | 942 | 0.360 |
Why?
|
| Epilepsy | 2 | 2022 | 111 | 0.360 |
Why?
|
| Rats, Sprague-Dawley | 6 | 2016 | 569 | 0.350 |
Why?
|
| Humans | 22 | 2024 | 59471 | 0.340 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2011 | 200 | 0.340 |
Why?
|
| Mutation | 1 | 2017 | 2445 | 0.330 |
Why?
|
| Rats | 6 | 2016 | 1914 | 0.300 |
Why?
|
| Sepsis | 1 | 2011 | 280 | 0.290 |
Why?
|
| Brain Injuries | 3 | 2016 | 138 | 0.280 |
Why?
|
| Wound Healing | 2 | 2019 | 177 | 0.260 |
Why?
|
| Neurons | 1 | 2011 | 860 | 0.260 |
Why?
|
| Magnetic Resonance Spectroscopy | 2 | 2023 | 293 | 0.240 |
Why?
|
| Male | 9 | 2024 | 27561 | 0.230 |
Why?
|
| Spinal Cord Stimulation | 1 | 2023 | 5 | 0.220 |
Why?
|
| Skull | 1 | 2023 | 57 | 0.220 |
Why?
|
| Stroke | 2 | 2011 | 1138 | 0.210 |
Why?
|
| Africa | 1 | 2022 | 21 | 0.210 |
Why?
|
| Subthalamic Nucleus | 1 | 2022 | 12 | 0.200 |
Why?
|
| Foramen Ovale | 1 | 2022 | 2 | 0.200 |
Why?
|
| Trigeminal Neuralgia | 1 | 2022 | 8 | 0.200 |
Why?
|
| Animals | 9 | 2016 | 19649 | 0.190 |
Why?
|
| Drug Resistant Epilepsy | 1 | 2022 | 17 | 0.190 |
Why?
|
| Neutrophils | 3 | 2015 | 351 | 0.180 |
Why?
|
| Cadaver | 2 | 2022 | 103 | 0.180 |
Why?
|
| Neurodegenerative Diseases | 1 | 2022 | 127 | 0.170 |
Why?
|
| Prevalence | 1 | 2024 | 1284 | 0.170 |
Why?
|
| Interleukin-6 | 2 | 2011 | 309 | 0.170 |
Why?
|
| Chronic Pain | 1 | 2022 | 142 | 0.170 |
Why?
|
| Decompressive Craniectomy | 1 | 2019 | 5 | 0.160 |
Why?
|
| Posterior Leukoencephalopathy Syndrome | 1 | 2019 | 12 | 0.160 |
Why?
|
| Aged | 2 | 2024 | 13342 | 0.150 |
Why?
|
| Nerve Growth Factors | 2 | 2015 | 28 | 0.150 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2017 | 49 | 0.140 |
Why?
|
| Multiple Sclerosis | 1 | 2019 | 208 | 0.140 |
Why?
|
| Treatment Outcome | 2 | 2024 | 5174 | 0.140 |
Why?
|
| Postpartum Period | 1 | 2019 | 203 | 0.140 |
Why?
|
| Infrared Rays | 1 | 2016 | 16 | 0.140 |
Why?
|
| Resins, Synthetic | 1 | 2016 | 2 | 0.130 |
Why?
|
| Cortical Spreading Depression | 1 | 2016 | 10 | 0.130 |
Why?
|
| Electrodes, Implanted | 1 | 2016 | 38 | 0.130 |
Why?
|
| Retrospective Studies | 2 | 2024 | 6007 | 0.130 |
Why?
|
| Glioblastoma | 1 | 2017 | 156 | 0.130 |
Why?
|
| Catheters | 1 | 2016 | 67 | 0.130 |
Why?
|
| Netrin-1 | 1 | 2015 | 4 | 0.120 |
Why?
|
| Cyclin D2 | 1 | 2015 | 6 | 0.120 |
Why?
|
| Infusions, Intraventricular | 1 | 2015 | 8 | 0.120 |
Why?
|
| Integrin alphaVbeta3 | 1 | 2015 | 14 | 0.120 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2024 | 2038 | 0.120 |
Why?
|
| Infant, Newborn | 1 | 2019 | 1306 | 0.120 |
Why?
|
| Image Enhancement | 1 | 2016 | 190 | 0.120 |
Why?
|
| Risk Factors | 1 | 2024 | 5010 | 0.110 |
Why?
|
| Peroxidase | 2 | 2011 | 69 | 0.110 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2015 | 194 | 0.110 |
Why?
|
| Sensitivity and Specificity | 1 | 2016 | 1094 | 0.110 |
Why?
|
| Cohort Studies | 1 | 2019 | 2443 | 0.110 |
Why?
|
| Recombinant Proteins | 1 | 2015 | 693 | 0.100 |
Why?
|
| Microtechnology | 1 | 2012 | 5 | 0.100 |
Why?
|
| Immunohistochemistry | 2 | 2011 | 847 | 0.100 |
Why?
|
| Glucose Oxidase | 1 | 2012 | 5 | 0.100 |
Why?
|
| Reproducibility of Results | 1 | 2016 | 1552 | 0.100 |
Why?
|
| Female | 3 | 2024 | 30895 | 0.100 |
Why?
|
| Skin | 1 | 2015 | 356 | 0.100 |
Why?
|
| Enzymes, Immobilized | 1 | 2012 | 16 | 0.100 |
Why?
|
| Electrochemical Techniques | 1 | 2012 | 15 | 0.100 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2011 | 53 | 0.100 |
Why?
|
| Catecholamines | 1 | 2011 | 31 | 0.100 |
Why?
|
| Multiple Organ Failure | 1 | 2011 | 43 | 0.090 |
Why?
|
| Vagotomy | 1 | 2011 | 8 | 0.090 |
Why?
|
| Drug Resistance | 1 | 2011 | 92 | 0.090 |
Why?
|
| Cerebrovascular Circulation | 1 | 2012 | 169 | 0.090 |
Why?
|
| Molecular Targeted Therapy | 1 | 2011 | 118 | 0.090 |
Why?
|
| Temperature | 1 | 2012 | 299 | 0.090 |
Why?
|
| Necrosis | 1 | 2011 | 138 | 0.090 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2011 | 59 | 0.090 |
Why?
|
| Tyrosine | 1 | 2011 | 93 | 0.090 |
Why?
|
| Biocompatible Materials | 1 | 2012 | 140 | 0.090 |
Why?
|
| Hippocampus | 2 | 2022 | 240 | 0.090 |
Why?
|
| Biosensing Techniques | 1 | 2012 | 114 | 0.090 |
Why?
|
| Oxygen | 1 | 2012 | 308 | 0.090 |
Why?
|
| Recovery of Function | 1 | 2011 | 261 | 0.080 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2011 | 525 | 0.080 |
Why?
|
| Blood Pressure | 1 | 2011 | 521 | 0.080 |
Why?
|
| Microglia | 1 | 2011 | 227 | 0.080 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2011 | 582 | 0.070 |
Why?
|
| Child | 1 | 2017 | 4308 | 0.070 |
Why?
|
| Middle Aged | 1 | 2024 | 16259 | 0.070 |
Why?
|
| Aging | 1 | 2011 | 723 | 0.060 |
Why?
|
| Head | 1 | 2023 | 52 | 0.050 |
Why?
|
| Globus Pallidus | 1 | 2022 | 24 | 0.050 |
Why?
|
| Meta-Analysis as Topic | 1 | 2022 | 77 | 0.050 |
Why?
|
| Death, Sudden | 1 | 2022 | 27 | 0.050 |
Why?
|
| Seizures | 1 | 2022 | 118 | 0.050 |
Why?
|
| Pain | 1 | 2023 | 405 | 0.040 |
Why?
|
| Intracranial Pressure | 1 | 2019 | 19 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2022 | 672 | 0.040 |
Why?
|
| Quality of Life | 1 | 2023 | 1118 | 0.030 |
Why?
|
| Neutrophil Infiltration | 1 | 2015 | 61 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2022 | 1463 | 0.030 |
Why?
|
| Neovascularization, Physiologic | 1 | 2015 | 102 | 0.030 |
Why?
|
| Adult | 2 | 2022 | 15771 | 0.030 |
Why?
|
| Microelectrodes | 1 | 2012 | 14 | 0.020 |
Why?
|
| S100 Calcium Binding Protein beta Subunit | 1 | 2011 | 7 | 0.020 |
Why?
|
| S100 Proteins | 1 | 2011 | 21 | 0.020 |
Why?
|
| Lactates | 1 | 2011 | 28 | 0.020 |
Why?
|
| Pregnancy | 1 | 2019 | 2354 | 0.020 |
Why?
|
| Cardiotonic Agents | 1 | 2011 | 48 | 0.020 |
Why?
|
| Drug Synergism | 1 | 2011 | 132 | 0.020 |
Why?
|
| Infarction, Middle Cerebral Artery | 1 | 2011 | 71 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2011 | 594 | 0.020 |
Why?
|
| Time Factors | 1 | 2012 | 3578 | 0.010 |
Why?
|